Skip to content

Released Nov 3, 2023, after the close

10-Q filed Nov 3, 2023, 34 days after period end · 0001628280-23-036777

Q3 2023 · 10-Q
Revenue$0.00no prior Q3 2022 on fileno prior Q2 2023 on file
Net Income-$50.71MN/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.55N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$51,459,000N/M
Operating Cash Flowderived-$39,166,000N/M
Free Cash Flowderived-$42,075,000N/M

What the release said

The release

Same quarter

MetricQ3 2023Q3 2022Q3 2021
Revenue$0.00——
Net Income-$50.71M-$29.35M-$16.41M
EPS Diluted-$0.55-$1.61-$1.52

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR